Trials / Terminated
TerminatedNCT03746587
Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
Multicentre Double-blinded, Randomized Placebo-controlled Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- ZevraDenmark · Industry
- Sex
- All
- Age
- 4 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter, doubleblinded, randomized placebo-controlled study of arimoclomol in patients with Gaucher Disease Type 1 or 3
Detailed description
Evaluating the response of 3 dose levels of arimoclomol on various pharmacodynamic biomarkers in blood and cerebrospinal fluid as indicators of enhanced GBA in Gaucher Disease Type 1 or 3.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arimoclomol | Arimoclomol in 3 different dosages |
| DRUG | Placebo oral capsule | Matching placebo capsule |
Timeline
- Start date
- 2018-06-06
- Primary completion
- 2020-04-01
- Completion
- 2021-10-15
- First posted
- 2018-11-19
- Last updated
- 2023-01-11
Locations
8 sites across 1 country: India
Source: ClinicalTrials.gov record NCT03746587. Inclusion in this directory is not an endorsement.